Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma

• Published in: Allergy, asthma, and clinical immunology asthma, and clinical immunology, 2017-02, Vol.13 (1), p.8-8, Article 8
• Main Authors: Caswell-Smith, Rachel, Cripps, Terrianne, Charles, Thom, Hosking, Alexander, Handigol, Meghana, Holweg, Cecile, Matthews, John, Holliday, Mark, Maillot, Corentin, Fingleton, James, Weatherall, Mark, Beasley, Richard, Braithwaite, Irene
• Format: Article
• Language: English
• Subjects: Asthma; Biological markers; Care and treatment; Monoclonal antibodies; Risk factors
• ISSN: 1710-1484; 1710-1492; 1710-1492
• DOI: 10.1186/s13223-017-0182-0

We aimed to determine the effect of sampling time during the day on serum periostin levels in adult participants with and without asthma. Serum periostin was measured at 2-h intervals from 0800 to 1800 h in 16 adult participants with stable asthma prescribed inhaled corticosteroid and long-acting beta-agonist therapy, and in 16 otherwise healthy participants without asthma. Mixed linear models were used to compare time zero (08:00 h) with subsequent measurement time for serum periostin for both groups. In both asthma and non-asthma, the mean (SD) serum periostin levels continuously reduced during the day from 53.5 (13.6) ng/mL at 0800 h to 50.9 (13.4) ng/mL at 1800 h (difference log periostin -0.05, P ≤ 0.001) and 50.5 (13.0) ng/mL at 0800 h to 46.2 (11.5) ng/mL at 1800 h (difference log periostin -0.08, P ≤ 0.001) respectively. Periostin values are higher in the morning compared with the afternoon in asthmatic and non-asthmatic adults. The small magnitude of the variation in serum periostin levels suggests that the time of day in which the serum periostin measurements are made is unlikely to influence treatment decisions if a specific serum periostin level is used to predict treatment responsiveness. Australia New Zealand Trials Registry (ACTRN12614000072617).